AS1708727 |
| Catalog No.GC62309 |
AS1708727 is an orally active Foxo1 inhibitor, with EC50 values of 0.33 μM and 0.59 μM for G6Pase and PEPCK, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1253226-93-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
AS1708727 is an orally active Foxo1 inhibitor, with EC50 values of 0.33 μM and 0.59 μM for G6Pase and PEPCK, respectively[1].
AS1708727 suppresses increases in blood glucose level by inhibiting gluconeogenic gene expression[1].
AS1708727 (30 to 300 mg/kg, orally) reduces both blood glucose and triglyceride levels, exhibiting anti-diabetic effects[1].
[1]. Hirotsugu Tanaka, et al. Effects of the Novel Foxo1 Inhibitor AS1708727 on Plasma Glucose and Triglyceride Levels in Diabetic Db/Db Mice. Eur J Pharmacol. 2010 Oct 25;645(1-3):185-91.
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *